Earnings Preview: Cardiff Oncology
Portfolio Pulse from Benzinga Insights
Cardiff Oncology (NASDAQ:CRDF) is set to release its latest quarterly earnings report on November 2, 2023. Analysts estimate an earnings per share (EPS) of $-0.28. The company's stock performance has been generally negative over the last 52-week period, with shares down 24.65%. Last quarter, the company beat EPS by $0.02, resulting in an 8.38% increase in the share price the next day.
November 01, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cardiff Oncology is expected to report an EPS of $-0.28 in its upcoming earnings report. The company's stock has been performing negatively, with a 24.65% decrease over the last 52 weeks. However, the previous quarter's EPS beat led to an 8.38% increase in the share price.
The upcoming earnings report is a significant event for Cardiff Oncology. The company's stock has been performing negatively over the past year, which may make investors cautious. However, the company's ability to beat EPS estimates in the past has had a positive impact on the share price. The direction of the stock price will likely depend on whether the company can beat the EPS estimate and provide positive guidance for the next quarter.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100